Our Pricing

Wegovy vs Saxenda: UK Prescription Weight Loss Comparison

Published on: June 03, 2026

Choosing between wegovy vs saxenda uk prescription options can feel overwhelming when both are MHRA-licensed injectable treatments for weight management. At Cured Pharmacy, our UK clinical team has guided thousands of patients through this decision, and this evidence-based comparison will help you understand which medication may be most suitable for your individual circumstances.

How Wegovy and Saxenda Work: The Science Behind GLP-1 Receptor Agonists

Both Wegovy (semaglutide) and Saxenda (liraglutide) belong to a class of medications called GLP-1 receptor agonists, which mimic a natural hormone that regulates appetite and blood sugar levels [1]. When you inject these medications, they bind to GLP-1 receptors in your brain and digestive system, slowing gastric emptying and reducing hunger signals. This dual mechanism helps you feel fuller for longer and consume fewer calories naturally.

The key difference lies in their molecular structure and duration of action. Semaglutide in Wegovy has been modified to remain active in your body for approximately one week, allowing once-weekly dosing [1]. Liraglutide in Saxenda has a shorter half-life of around 13 hours, requiring daily injections to maintain therapeutic levels [2]. This structural difference significantly impacts both convenience and clinical outcomes, as we'll explore throughout this comparison.

Wegovy vs Saxenda: Clinical Trial Results and Weight Loss Efficacy

The STEP 1 trial demonstrated that patients using Wegovy achieved an average weight reduction of 14.9% of their initial body weight over 68 weeks, compared to 2.4% with placebo [1]. In contrast, the SCALE Obesity and Prediabetes trial showed Saxenda users lost an average of 8.0% of their body weight over 56 weeks, compared to 2.6% with placebo [2]. These results suggest that semaglutide-based Wegovy may produce greater weight loss outcomes in clinical trial settings.

However, individual responses vary considerably based on adherence, lifestyle modifications, and metabolic factors. During consultations at Cured Pharmacy, our prescribers assess your medical history, previous weight loss attempts, and treatment goals to determine which medication aligns best with your circumstances. Both treatments require commitment to dietary changes and increased physical activity to achieve optimal results, as medications alone are not a complete solution [3].

Real-World Effectiveness Beyond Clinical Trials

While clinical trial data provides valuable insights, real-world effectiveness can differ due to varying adherence patterns and patient populations. Our clinical team at Cured Pharmacy has observed that patients who maintain consistent injection schedules, attend follow-up consultations, and implement sustainable lifestyle changes tend to achieve results comparable to trial outcomes. The once-weekly convenience of Wegovy may support better long-term adherence for some patients, whilst others prefer the daily routine and lower per-injection dose of Saxenda.

Dosing Schedules: Once Weekly vs Daily Injections

Wegovy follows a gradual dose escalation protocol starting at 0.25mg once weekly, increasing monthly until reaching the maintenance dose of 2.4mg weekly [4]. This titration schedule, spanning approximately 16-20 weeks, helps minimise gastrointestinal side effects whilst your body adjusts to the medication. You'll inject Wegovy on the same day each week, making it easier to integrate into your routine.

Saxenda requires daily subcutaneous injections, starting at 0.6mg and increasing by 0.6mg increments weekly until reaching the maintenance dose of 3.0mg daily [2]. The daily dosing provides more flexibility to adjust timing around your schedule, though it requires consistent adherence seven days per week. Some patients find daily injections more manageable psychologically, whilst others prefer the convenience of weekly dosing. Your UK prescriber will discuss which schedule fits your lifestyle and medical needs during your consultation.

Injection Technique and Administration

Both medications are administered via subcutaneous injection into the abdomen, thigh, or upper arm using pre-filled pen devices. The injection process takes less than a minute once you're familiar with the technique, and our clinical team provides comprehensive guidance during your first prescription. Wegovy pens are single-dose and disposed of after each weekly injection, whilst Saxenda pens contain multiple doses and last approximately six days at the maintenance dose.

Common Side Effects: What to Expect with Wegovy vs Saxenda

Gastrointestinal side effects are the most frequently reported adverse events with both medications, including nausea, vomiting, diarrhoea, and constipation [1][2]. In the STEP trials, approximately 44% of Wegovy users experienced nausea, typically most pronounced during dose escalation phases [1]. Similarly, around 39% of Saxenda users in SCALE trials reported nausea, though the daily dosing pattern may produce a different side effect profile for some individuals [2].

Most gastrointestinal symptoms improve within 4-8 weeks as your body adapts to the medication. Our superintendent pharmacist Tarun Kumar recommends eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated to manage these effects. Serious side effects are rare but can include pancreatitis, gallbladder problems, and changes in heart rate. Both medications carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [4][5]. Your prescriber will review your complete medical history to ensure either medication is appropriate for you.

Eligibility Criteria and Contraindications for UK Patients

In the UK, both Wegovy and Saxenda are licensed for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4][5]. NICE guidelines recommend considering GLP-1 receptor agonists as part of a comprehensive weight management programme that includes dietary modification, increased physical activity, and behavioural support [3].

Neither medication is suitable if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Saxenda is contraindicated in pregnancy and breastfeeding, and Wegovy should be discontinued at least two months before planned conception due to its longer half-life [4][5]. During your free online consultation at Cured Pharmacy, our UK-registered prescribers will assess your medical history, current medications, and treatment goals to determine eligibility and recommend the most appropriate option subject to clinical approval.

Special Considerations for Patients with Type 2 Diabetes

Both medications can be prescribed for weight management in patients with type 2 diabetes, though dosing and monitoring requirements may differ. If you're currently taking other diabetes medications, particularly insulin or sulfonylureas, your prescriber may need to adjust doses to reduce hypoglycaemia risk. Regular blood glucose monitoring becomes particularly important during the initial months of treatment as weight loss and improved insulin sensitivity can significantly alter your glycaemic control.

Wegovy vs Saxenda UK: Cost, Availability, and Treatment Duration

At Cured Pharmacy, Wegovy is available from £79.00 per pen, with transparent upfront pricing displayed before your consultation. Treatment duration varies based on individual response and weight loss goals, though clinical trials typically evaluated outcomes over 56-68 weeks [1][2]. NICE guidance suggests continuing treatment only if patients achieve at least 5% weight loss after 12 weeks at maintenance dose, ensuring medications are used effectively [3].

Both treatments require ongoing prescription and clinical monitoring, as they are not intended for short-term use. Our clinical team conducts regular reviews to assess progress, manage side effects, and determine appropriate treatment duration. Some patients achieve their weight loss goals within 6-12 months, whilst others benefit from longer-term maintenance therapy to prevent weight regain. The total cost will depend on your prescribed dose, treatment duration, and individual response, which your UK prescriber will discuss during your consultation.

Supply Considerations in the UK Market

The UK has experienced intermittent supply constraints for both medications due to increased global demand. At Cured Pharmacy, we work directly with licensed UK wholesalers to maintain reliable stock of genuine MHRA-approved medications. If your preferred treatment is temporarily unavailable, our clinical team can discuss alternative options or notify you when supply resumes. We never substitute medications without prescriber approval and patient consent.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
5. Novo Nordisk. (2023). Saxenda 6 mg/ml solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/2313 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, lifestyle modifications, and metabolic response.